Skip to main content

Table 5 MEK inhibitors in clinical trials

From: MEK inhibitors for the treatment of non-small cell lung cancer

Study

Phase

MEK inhibitors

Drug therapy

Hainsworth et al. [36]

Phase II

Selumetinib

MEKi

Haura et al. [37]

Phase II

Mirdametinib

MEKi

Blumenschein et al. [38]

Phase II

Trametinib

MEKi

Lopez-Chavez et al. [39]

Phase II

Selumetinib

MEKi

Planchard et al. [40]

Phase II

Trametinib

MEKi + BRAFi

Planchard et al. [41]

Phase II

Trametinib

MEKi + BRAFi

Salama et al. [42]

Phase II

Trametinib

MEKi + BRAFi

Jänne et al. [43]

Phase II

Selumetinib

MEKi + CT

Gandara et al. [46]

Phase I/ Ib

Trametinib

MEKi + CT

Jänne et al. [47]

Phase III

Selumetinib

MEKi + CT

Soria et al. [49]

Phase II

Selumetinib

MEKi + CT

Greystoke et al. [50]

Phase I

Selumetinib

MEKi + CT

Seto et al. [51]

Phase I

Selumetinib

MEKi + CT

Melosky et al. [44]

Phase II

Selumetinib

MEKi + CT

Hellmann et al. [56]

Phase Ib

Cobimetinib

MEKi + ICI

Gaudreau et al. [57]

Phase I/II

Trametinib

MEKi + ICI

Carter et al. [59]

Phase Ib

Selumetinib

MEKi + EGFR-TKI

Oxnard et al. [60]

Phase Ib

Selumetinib

MEKi + EGFR-TKI

  1. MEKi, MEK inhibitors, BRAFi, BRAF inhibitors, CT, chemotherapy, ICI, immune checkpoint inhibitors, EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitors